Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation

Bull Exp Biol Med. 2012 Oct;153(6):878-81. doi: 10.1007/s10517-012-1849-7.
[Article in English, Russian]

Abstract

We studied the expression of peroxiredoxin genes (PRDX1, PRDX2, PRDX3, and PRDX6) in human erythroleukemia K652, human breast carcinoma MCF-7, and human ovarian carcinoma SKOV-3 cells during cisplatin resistance development. It was found that drug resistance formation was accompanied by a significant increase in the expression of PRDX1, PRDX2, PRDX3, PRDX6 genes in all cancer cell strains, which confirms the important contribution of redox-dependent mechanisms into the development of cisplatin resistance of cancer cells.

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / genetics*
  • Carcinoma / drug therapy
  • Carcinoma / enzymology
  • Carcinoma / genetics*
  • Cell Line, Tumor
  • Cisplatin / pharmacology
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Gene Expression / drug effects
  • Humans
  • Leukemia, Erythroblastic, Acute / drug therapy
  • Leukemia, Erythroblastic, Acute / enzymology
  • Leukemia, Erythroblastic, Acute / genetics*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / enzymology
  • Ovarian Neoplasms / genetics*
  • Oxidative Stress
  • Peroxiredoxin III / genetics*
  • Peroxiredoxin III / metabolism
  • Peroxiredoxin VI / genetics*
  • Peroxiredoxin VI / metabolism
  • Peroxiredoxins / genetics*
  • Peroxiredoxins / metabolism

Substances

  • Antineoplastic Agents
  • PRDX1 protein, human
  • PRDX2 protein, human
  • PRDX3 protein, human
  • PRDX6 protein, human
  • Peroxiredoxin III
  • Peroxiredoxin VI
  • Peroxiredoxins
  • Cisplatin